EA201991788A1 - Улучшенные моноклональные анти-vegr-2 антитела - Google Patents

Улучшенные моноклональные анти-vegr-2 антитела

Info

Publication number
EA201991788A1
EA201991788A1 EA201991788A EA201991788A EA201991788A1 EA 201991788 A1 EA201991788 A1 EA 201991788A1 EA 201991788 A EA201991788 A EA 201991788A EA 201991788 A EA201991788 A EA 201991788A EA 201991788 A1 EA201991788 A1 EA 201991788A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monoclonal anti
antibody
vegr
antibodies
improved monoclonal
Prior art date
Application number
EA201991788A
Other languages
English (en)
Inventor
И Бай
Сянго Гу
Original Assignee
Бейдзин Дунфан Байотек Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейдзин Дунфан Байотек Ко., Лтд. filed Critical Бейдзин Дунфан Байотек Ко., Лтд.
Publication of EA201991788A1 publication Critical patent/EA201991788A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к технической области биомедицины. Предложено улучшенное моноклональное анти-VEGFR-2 (рецептора 2 фактора роста эндотелия сосудов) и его применение. Посредством метода компьютерного моделирования разработана новая фаговая библиотека антител, и после нескольких раундов скрининга получено улучшенное моноклональное анти-VEGR-2 антитело. И аффинность, и биологическая активность указанного антитела выше, чем у исходного антитела. Указанное антитело способно эффективно ингибировать связывание VEGFR-2 и его лиганда, VEGF (фактор роста эндотелия сосудов), in vitro и может быть использовано в лечении опухоли и заболевания, вызванного ангиогенезом, такого как макулярная дегенерация.
EA201991788A 2017-03-07 2018-02-14 Улучшенные моноклональные анти-vegr-2 антитела EA201991788A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710130518.0A CN106674349B (zh) 2017-03-07 2017-03-07 一种改进的抗vegfr‑2单克隆抗体
PCT/CN2018/076847 WO2018161798A1 (zh) 2017-03-07 2018-02-14 一种改进的抗vegfr-2单克隆抗体

Publications (1)

Publication Number Publication Date
EA201991788A1 true EA201991788A1 (ru) 2020-02-28

Family

ID=58828620

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991788A EA201991788A1 (ru) 2017-03-07 2018-02-14 Улучшенные моноклональные анти-vegr-2 антитела

Country Status (9)

Country Link
US (1) US11370834B2 (ru)
EP (1) EP3590964A4 (ru)
JP (1) JP6843262B2 (ru)
KR (1) KR102276489B1 (ru)
CN (1) CN106674349B (ru)
AU (1) AU2018229915B2 (ru)
CA (1) CA3054615C (ru)
EA (1) EA201991788A1 (ru)
WO (1) WO2018161798A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106674349B (zh) 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体
WO2021013061A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
CN111024949A (zh) * 2019-12-31 2020-04-17 上海博威生物医药有限公司 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用
CN112094351B (zh) * 2020-09-11 2021-04-20 北京东方百泰生物科技股份有限公司 一种抗vegfr-2单克隆抗体的检测性抗体、应用及检测方法
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
CN115957319B (zh) * 2022-10-14 2023-06-30 北京东方百泰生物科技股份有限公司 一种抗nkg2a单克隆抗体的注射制剂
CN116254315A (zh) * 2022-12-23 2023-06-13 北京东方百泰生物科技股份有限公司 一种vegf/vegfr抑制剂生物学活性的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510561T1 (de) * 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
CN103012589B (zh) * 2012-12-11 2014-07-16 上海赛伦生物技术有限公司 人源抗人血管内皮细胞生长因子抗体及其应用
CN103965355A (zh) * 2013-02-06 2014-08-06 中国医学科学院基础医学研究所 针对VEGFR2的全人源抗体重链和轻链可变区及相应Fab和全长抗体
CN103965356A (zh) * 2013-02-06 2014-08-06 中国医学科学院基础医学研究所 针对VEGFR2的全人源抗体重链和轻链可变区及相应Fab和全长抗体
CN103333247B (zh) * 2013-05-30 2014-10-08 北京东方百泰生物科技有限公司 新型抗vegfr2的单克隆抗体及其制备与应用
CN103525868B (zh) 2013-10-17 2015-01-21 百泰生物药业有限公司 哺乳动物细胞高效表达载体的构建及应用
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
BR112017022205A2 (pt) * 2015-04-14 2018-08-28 Academia Sinica anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
KR20180021136A (ko) * 2015-06-30 2018-02-28 헨리우스 바이오테크 컴퍼니 리미티드 항-혈관 내피 성장 인자 수용체 2 (vegfr2) 항체
CN106674349B (zh) * 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体

Also Published As

Publication number Publication date
US11370834B2 (en) 2022-06-28
KR20190113876A (ko) 2019-10-08
JP6843262B2 (ja) 2021-03-17
JP2020510427A (ja) 2020-04-09
CN106674349A (zh) 2017-05-17
AU2018229915B2 (en) 2020-10-08
CA3054615A1 (en) 2018-09-13
US20210139575A1 (en) 2021-05-13
CN106674349B (zh) 2018-03-13
CA3054615C (en) 2022-08-02
AU2018229915A1 (en) 2019-09-19
WO2018161798A1 (zh) 2018-09-13
EP3590964A4 (en) 2020-03-25
EP3590964A1 (en) 2020-01-08
KR102276489B1 (ko) 2021-07-13

Similar Documents

Publication Publication Date Title
EA201991788A1 (ru) Улучшенные моноклональные анти-vegr-2 антитела
EA201891165A1 (ru) Молекулы, связывающие pd1 и/или lag3
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
EA201891166A1 (ru) Ctla4-связывающие вещества
MX2017008662A (es) Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PH12018502560A1 (en) Anti-c5 antibodies and uses thereof
EA201890143A3 (ru) Антитела против pdgfr-бета и их применения
EA201792451A1 (ru) Антитела к ox40 и способы их применения
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201691027A1 (ru) Модуляторы aplnr и их применение
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
CR20120454A (es) Proteínas terapéuticas de unión a dll4
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201892097A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ
EA202091747A1 (ru) Составы антитела b7-h4
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202091569A1 (ru) Моноклональные антитела и способы их применения
EA201492162A1 (ru) Антитела к трансглютаминазе 2
EA201892094A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ